UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)*

Entera Bio Ltd.

(Name of Issuer)

Ordinary Shares, par value NIS 0.0000769 per share (Title of Class of Securities)

M40527109 (CUSIP Number)

December 31, 2020
(Date of Event Which Requires Filing of this Statement)

 	 _		
☐ Rule 13d-1(d)			
⊠ Rule 13d-1(c)			
☐ Rule 13d-1(b)			

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the *Securities Exchange Act* of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

No. M	P No. M40527109		13G	Page 2 of 6 Pages			
1	NAME OF REPORT	TING PERSON	S				
	Capital Point Ltd.						
2		OPRIATE BOX	X IF A MEMBER OF A GROUP (See instruction	ns)			
	(a) 🗆		,	,			
	(b) 🗆						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
	Israel	5	SOLE VOTING POWER				
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		3	SOLE VOTING FOWER				
			1,147,385 (*)				
		6	SHARED VOTING POWER				
		7	SOLE DISPOSITIVE POWER				
		-					
			1,147,385 (*)				
		8	SHARED DISPOSITIVE POWER				
9	AGGREGATE AMO	OUNT BENEFI	CIALLY OWNED BY EACH REPORTING PER	RSON			
	4.4.7.005 (4)						
10	1,147,385 (*) CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)						
10	CHECK IF THE AC	UKEUATE AN	IOUNT IN ROW (9) EXCLUDES CERTAIN SE	IAKES (See Instructions)			
11	PERCENT OF CLA	SS REPRESEN	TED BY AMOUNT IN ROW 9				

TYPE OF REPORTING PERSON (See instructions)

12

CO

^(*) Comprised of (i) 1,077,621 ordinary shares, and (ii) a warrant to purchase 69,764 ordinary shares.

^(**) Based on 21,057,922 ordinary shares outstanding as of December 31, 2020, as provided by the Issuer, and warrants to purchase 69,764 ordinary shares held by the Reporting Persons.

	Entera Bio Ltd.				
(b)	Address of Issuer's Principal Executive Offices:				
	Kiryat Hadassah, Minrav Building – Fifth Floor Jerusalem 9112002, Israel				
Item 2. (a)	Name of Person Filing:				
	Capital Point Ltd.				
(b) Address of Principal Business Office:					
Azrieli 1, Tel Aviv 67021, Israel					
(c)	Citizenship:				
	Israel				
(d)	Title of Class of Securities:				
	Ordinary Shares, par value of NIS 0.0000769				
(e)	CUSIP Number:				
	M40527109				
Item 3.	Not applicable				
Item 4.	Ownership:				
(a)	Amount beneficially owned:				
	See rows 5-9 of cover page of the reporting person.				
	3				

Item 1. (a)

Name of Issuer:

Percent of class: (b) See row 11 of cover page of each reporting person Number of shares as to which such person has: (c) (i) Sole power to vote or to direct the vote: See row 5 of cover page of each reporting person (ii) Shared power to vote or to direct the vote: See row 6 of cover page of each reporting person and note in Item 4(a) above (iii) Sole power to dispose or to direct the disposition of: See row 7 of cover page of each reporting person (iv) Shared power to dispose or to direct the disposition of: See row 8 of cover page of each reporting person and note in Item 4(a) above Ownership of Five Percent or Less of a Class: Not applicable

Item 5.

Item 6. Ownership of More than Five Percent on Behalf of Another:

Not applicable

Item 7.	<u>Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person</u> :
	Not applicable
Item 8.	Identification and Classification of Members of the Group:
	Not applicable
Item 9.	Notice of Dissolution of Group:
	Not applicable
Item 10.	Certification:
	Not applicable
	5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 15, 2021

Capital Point Ltd.

/s/ Shay Lior By: Shay Lior

Title: Co-Chief Executive Officer

/s/ Yossi Tamar By: Yossi Tamar

Title: Co-Chief Executive Officer